Shares of Vaxart cratered 58% on Feb. 3 after early preliminary trial data showed that its oral COVID-19 vaccine did not produce neutralizing antibodies in “most subjects.” At the same time, Vaxart (VXRT) reported that the preliminary data from the Phase 1 study of VXA-CoV2-1, its oral COVID-19 tablet vaccine candidate, did trigger multiple immune responses against SARS-CoV-2 antigens, but neutralizing antibodies weren’t detected. Following the study, a total of 495 individuals have now been dosed with Vaxart’s platform, with no serious adverse events.